Status:

COMPLETED

Enoxaparin in Acute Venous Thromboembolic Disease

Lead Sponsor:

Sanofi

Conditions:

Venous Thrombosis

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

Study objectives : * To evaluate the efficacy/safety profile of enoxaparin once a day treatment in acute venous thromboembolic disease.

Eligibility Criteria

Inclusion

  • Patients with symptomatic lower-extremity deep venous thrombosis confirmed by doppler USG (ultrasonography), with or without confirmed symptomatic pulmonary embolism associated with provoked risk factors

Exclusion

  • Patients with a history of heparin or warfarin treatment longer than 24 hours,
  • Patients requiring thrombolytic treatment,
  • Patients having thrombophilia diagnosis,
  • Patients with prior deep vein thrombosis or pulmonary emboli evidence,
  • Patients with familial bleeding disorder,
  • Patients who are at any known bleeding risk, such as active bleeding, active ulcerative bowel disease, angiodysplasia and having oculary, spinal or central nervous system surgery within the last month
  • Patients with renal failure (serum creatinine concentration \> 180 mmol/L or \> 2.03 mg/dL),
  • Patients with severe hepatic failure
  • Patients with history of allergy against heparin and protamine,
  • Patients with history of thrombocytopenia associated with heparin administration or of skin necrosis after heparin or warfarin treatment,
  • Patients participating in another clinical study within the last 4 months
  • Patients who are pregnant
  • The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Key Trial Info

Start Date :

December 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2009

Estimated Enrollment :

251 Patients enrolled

Trial Details

Trial ID

NCT00265993

Start Date

December 1 2004

End Date

January 1 2009

Last Update

February 3 2010

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Sanofi-Aventis Administrative Office

Istanbul, Turkey (Türkiye)